A

	HEAL-26	EGFY-32	KTTI-32	GQKG-32	TWTT-28	TSASI-28	GVLP-28	ATYN-17
NetMHC DR2 binding prediction	+	-	-	+	-	-	-	+
IEDB DR2 binding prediction	+	-	-	-	-	-	+	+
Proliferation induction	++++	++	-	-	+++	-	+++	+ ++




FIG. 1



HEAL 125 S2
HEAL 105 S2
HEAL 26 S2
HEAL 38 S1
HEAL 25 S2
IL-2 (pg/ml)
thymidine incorporation (ccpm)
Fresh
Fixed
HEAL26
DMSO
POP-1
POP-2
POP-3
POP-4
POP-5
POP-6
POP-7
POP-8
POP-9
POP-10
POP-11
POP-12

FIG. 2



TWTT 32 HK
TWTT 25 HK
TWTT 66
TWTT 18
TWTT 59
Not fixed
fixed
IL-2 (pg/ml)
TWTT28
DMSO
POP-13
POP-14
POP-15
POP-16
POP-17
POP-18
POP-19
POP-20
AFPS
TSAS

FIG. 3



GVLP 193 S1mean
Not fixed
fixed
IL-2 (pg/ml)
15000
10000
5000
0
GVLP
DMSO
POP-21
POP-22
POP-23
POP-24
POP-25
POP-26
POP-27
POP-28
POP-29
POP-30
POP-31
POP-32
POP-33
POP-34

FIG. 4



Amount of apitope injected s.c
0.1 µg
1 µg
10 µg
100 µg
Long peptide/CFA tail base
d-15
d-13
d-11
d-8
d-6
d-4
d0
d10
Splenocytes and LNC culture with long peptide
3 days
Proliferation and cytokine assay

FIG. 5



A
thymidine incorporation (cpm)
PBS
POP-4
thymidine incorporation (cpm) PPD
HEAL-26 (µg/ml)
PPD
B
SI
p=0.008
p=0.03
50/PBS
10/PBS
1/PBS
0.1/PBS
0.01/PBS
50/POP-4
10/POP-4
1/POP-4
0.1/POP-4
0.01/POP-4
C
IL-1α
IL-4
IL-5
IL-10
IL-2
IFN-γ
p=0.08
TNF-α
GM-CSF
IL-6
IL-17
p=0.09
pg/ml
PBS/50
PBS/0
POP-4/50
POP-4/0

FIG. 6



A
PBS
POP-4
thymidine incorporation (ccpm)
HEAL-26 (µg/ml)
PPD
B
SI
p=0.001
p=0.003
p=0.003
50PBS
10PBS
1PBS
0.1PBS
0.01PBS
50POP-4
10POP-4
1POP-4
0.1POP-4
0.01POP-4
C
IL-1α
IL-4
IL-5
IL-10
IL-2
p=0.005
IFN-γ
TNF-α
p=0.01
GM-CSF
IL-6
IL-17
p=0.08
pg/ml
PBS/50
PBS/0
POP-4/50
POP-4/0

FIG. 7



A
TWTT-28
PBS
thymidine incorporation (ccpm)
thymidine incorporation (cpm)
TWTT-28 (µg/ml)
PPD
B
SI
50/PBS
10/PBS
1/PBS
0.1/PBS
0.01/PBS
50/TWTT-28
10/TWTT-28
1/TWTT-28
0.1/TWTT-28
0.01/TWTT-28
C
IL-1α
IL-4
IL-5
IL-10
IL-2
IFN-γ
TNF-α
GM-CSF
IL-6
IL-17
pg/ml
PBS/10
PBS/0
TWTT-28/10
TWTT-28/0
p=0.09
p=0.03
p=0.02
p=0.02

FIG. 8



A
PBS
TWTT-28
thymidine incorporation (cpm)
TWTT-28 (µg/ml)
PPD
B
SI
C
IL-1α
IL-4
IL-5
IL-10
IL-2
IFN-γ
TNF-α
GM-CSF
IL-6
IL-17
pg/ml
p=0.008
p=0.02
p=0.007
p=0.005
PBS/10
PBS/0
TWTT-28/10
TWTT-28/0

FIG. 9



A
POP-15
PBS
thymidine incorporation (ccpm)
thymidine incorporation (ccpm) PPD
TWTT-28 (µg/ml)
B
SI
p=0.032
p=0.095
p=0.095
p=0.016
p=0.095
50/PBS
10/PBS
1/PBS
0.1/PBS
0.01/PBS
50/POP-15
10/POP-15
1/POP-15
0.1/POP-15
0.01/POP-15
C
IL-1α
p=0. 07
IL-4
IL-5
IL-10
IL-2
IFN-γ
p=0.06
TNF-α
GM-CSF
p=0.04
IL-6
IL-17
p=0.02
pg/ml
PBS/50
PBS/0
POP-15/50
POP-15/0

FIG. 10



A
PBS
POP-15
thymidine incorporation (cpm)
thymidine incorporation (cpm) PPD
TWTT-28 (µg/ml)
B
SI
C
IL-1α
IL-4
IL-5
IL-10
IL-2
IFN-γ
p=0.007
TNF-α
GM-CSF
IL-6
IL-17
pg/ml
PBS/50
PBS/0
POP-15/50
POP-15/0

FIG. 11



A
PBS
POP-22
thymidine incorporation (ccpm)
thymidine incorporation (ccpm) PPD
GVLP-28 (µg/ml)
B
SI
50/PBS
10/PBS
1/PBS
0.1/PBS
0.01/PBS
50/POP-22
10/POP-22
1/POP-22
0.1/POP-22
0.01/POP-22
C
IL-1α
p=0.07
IL-4
IL-5
IL-10
IL-2
IFN-γ
TNF-α
GM-CSF
IL-6
IL-17
p=0.06
pg/ml
PBS/50
PBS/0
POP-22/50
POP-22/0

FIG. 12



A
PBS
POP-22
thymidine incorporation (ccpm)
25000
20000
15000
10000
5000
0
55000
50000
45000
40000
35000
thymidine incorporation (ccpm) PPD
50
10
1
0.1
0.01
0
PPD
GVLP-28 (µg/ml)
B
SI
4
3
2
1
0
50/PBS
10/PBS
1/PBS
0.1/PBS
0.01/PBS
10/POP-22
1/POP-22
0.1/POP-22
0.01/POP-22

FIG. 13



A
PBS
GVLP-28
POP-22
thymidine incorporation (ccpm)
thymidine incorporation (ccpm) PPD
GVLP-28 (µg/ml)
B
SI
50/PBS
10/PBS
1/PBS
0.1/PBS
0.01/PBS
50/POP-22
10/POP-22
1/POP-22
0.1/POP-22
0.01/POP-22
50/GVLP-28
10/GVLP-28
1/GVLP-28
0.1/GVLP-28
0.01/GVLP-28

FIG. 14



A
PBS
GVLP-28
POP-22
thymidine incorporation (ccpm)
thymidine incorporation (ccpm) PPD
GVLP-28 (µg/ml)

FIG. 15




FIG. 15 (continued)